Johnson & Johnson is a buy as drug sales continue to improve, Wells Fargo says

Wells Fargo upgraded Johnson & Johnson to Overweight from Equal Weight, raising its price target to $212 (14% upside), driven by executive projections for strong medicine sales through 2027 and significant expansion of U.S. drug manufacturing. The bank cited JNJ's confidence in pharmaceutical growth, including demand for cancer treatments and improved margins, supported by a $55 billion investment in R&D and manufacturing, and a history of exceeding revenue targets. This positive outlook, shared by a majority of analysts, led to a ~1% premarket stock increase.

Analysis

Wells Fargo has upgraded Johnson & Johnson (JNJ) to Overweight with a new price target of $212, implying a 14% upside, based on a strongly positive outlook for its pharmaceutical division. The bank's confidence is rooted in JNJ executives' projection of accelerating pharmaceutical sales from 2025 to 2027, a forecast that notably diverges from more conservative Street estimates. This optimistic guidance is substantiated by the company's recent performance, including exceeding its $57 billion pharmaceutical revenue goal for 2025 a year ahead of schedule, and growing demand for key cancer treatments like Rybrevant. A critical factor in the upgrade is the belief that JNJ can successfully navigate the upcoming Loss of Exclusivity (LOE) for its drug Stelara, a key concern for investors. Financially, margins are expected to improve as tariff headwinds moderate. Strategically, JNJ is bolstering its resilience against future trade and supply chain disruptions by investing $55 billion in U.S.-based research and manufacturing over the next four years, which includes a $2 billion facility expansion in North Carolina. This bullish sentiment from Wells Fargo aligns with the majority of analysts, as 14 of 27 covering the stock maintain a buy or strong buy rating.

Key Decisions for Investors

• Investors should view the Wells Fargo upgrade as a catalyst, supported by management's confident multi-year sales guidance which contrasts with current market consensus, suggesting potential for upside surprise.
• Monitor the performance of JNJ's pharmaceutical division, particularly its ability to meet or exceed sales targets through the Stelara patent cliff, as this is the central pillar of the bullish thesis.
• Consider the long-term de-risking of the business through the $55 billion domestic investment, as this strategic shift is poised to enhance supply chain security and improve margins, justifying a potentially higher valuation multiple.